Skip to main content
. 2020 Mar 14;35(6):1055–1066. doi: 10.1007/s00384-020-03557-3

Table 1.

Patients’ and tumour characteristics for 2158 patients

Clavien-Dindo classification All
n = 2158
0
n = 1691
I
n = 141
II
n = 162
III
n = 112
IV
n = 52
p
N (%) n (%) n (%) n (%) n (%) n (%)
Age median (range) (years) 64.5 (17–94) 64 (17–94) 66 (21–87) 67 (36–93) 65 (35–88) 71 (39–90) < 0.001
  Sex
  Male 1351 (62.6) 1038 (61.4) 92 (65.2) 99 (61.1) 87 (77.7) 35 (67)
  Female 807 (37.4) 653 (38.6) 49 (34.8) 63 (38.9) 25 (22.3) 17 (33) 0.011
ASA*
  ASA I–II 1498 (81.7) 1200 (83.7) 93 (77.5) 114 (78.6) 65 (69.9) 26 (61)
  ASA III–IV 336 (18.3) 233 (16.3) 27 (22.5) 31 (21.4) 28 (30.1) 17 (40) < 0.001
Tumour site
  Colon 990 (45.9) 807 (47.7) 61 (43.3) 62 (38.3) 33 (29.5) 27 (52)
  Rectum 1168 (54.1) 884 (52.3) 80 (56.7) 100 (61.7) 79 (70.5) 25 (48) < 0.001
Surgical procedure
  (Low) anterior resection 951 (44.1) 747 (44.2) 48 (34.0) 77 (47.5) 57 (50.9) 22 (42)
  Abdominoperineal excision 216 (10.0) 138 (8.2) 30 (21.3) 23 (14.2) 22 (19.6) 3 (6)
  Colon standard resection 787 (36.5) 656 (38.8) 40 (28.4) 50 (30.9) 26 (23.2) 15 (29)
  Colon extended resection 204 (9.5) 150 (8.9) 23 (16.3) 12 (7.4) 7 (6.3) 12 (23) < 0.001
  Multivisceral resection 246 (11.4) 170 (10.1) 26 (18.4) 23 (14.2) 17 (15.2) 10 (19) 0.003
Multimodal treatment
  Neoadjuvant treatment 550 (25.5) 420 (24.8) 37 (26.2) 43 (26.5) 39 (34.8) 11 (21.2) 0.187
  Adjuvant treatment 658 (30.5) 537 (31.8) 44 (31.2) 41 (25.3) 28 (25.0) 8 (15.4) 0.032
  Adjuvant treatment for   rectal carcinoma stage II,III 162/342 (47.4) 126/253 (49.8) 10/29 (34) 11/34 (32) 10/17 (59) 5/9 (56) 0.150
  Adjuvant treatment for colon carcinoma stage III 215/312 (68.9) 186/257 (72.4) 14/17 (82) 10/15 (67) 5/12 (42) 0/11 (0) < 0.001
pT category
  pT1,2/ypT0,1,2 998 (46.2) 790 (46.7) 53 (37.6) 76 (46.9) 59 (52.7) 20 (38)
  pT3/ypT3 1028 (47.6) 801 (47.4) 80 (56.7) 74 (45.7) 45 (40.2) 28 (54)
  pT4/ypT4 132 (6.1) 100 (5.9) 8 (5.7) 12 (7.4) 8 (7.1) 4 (8) 0.309
pN category
  pN0/ypN0 1491 (69.1) 1166 (69.0) 95 (67.4) 119 (73.5) 81 (72.3) 30 (58)
  pN1,2/ypN1,2 667 (30.9) 525 (31.0) 46 (32.6) 43 (26.5) 31 (27.7) 22 (42) 0.290
Stage (UICC)
  Stage I 573 (26.6) 454 (26.8) 32 (22.7) 42 (25.9) 33 (29.5) 12 (23)
  Stage II 535 (24.8) 424 (25.1) 37 (26.2) 46 (28.4) 17 (15.2) 11 (21)
  Stage III 500 (23.2) 393 (23.2) 35 (24.8) 31 (19.1) 23 (20.5) 18 (35)
  Stage y0 73 (3.4) 60 (3.5) 2 (1.4) 4 (2.5) 7 (6.3) 0
  Stage yI 164 (7.6) 127 (7.5) 6 (4.3) 17 (10.5) 12 (10.7) 2 (4)
  Stage yII 146 (6.8) 101 (6.0) 18 (12.8) 10 (6.2) 12 (10.7) 5 (10)
  Stage yIII 167 (7.7) 132 (7.8) 11 (7.8) 12 (7.4) 8 (7.1) 4 (8) 0.045

ASA American Society of Anesthesiologists Classification; *ASA missing in 324 patients